Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.

European journal of cancer (Oxford, England : 1990) - 1 Jul 2022

Karamitopoulou Eva, Andreou Andreas, Wenning Anna Silvia, Gloor Beat, Perren Aurel

Abstract excerpt

AIM: Tumor mutational burden (TMB: somatic mutations per megabase, mut/Mb) predicts the efficacy of immunotherapy. Here, we link TMB levels with the activation of immune pathways and intratumoral immune responses in pancreatic adenocarcinoma (PDAC) to explore immunoarchitectural patterns associated with high TMB. METHODS: We assessed TMB in 161 resected, microsatellite stable (MSS) PDACs, including 41 long-term...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microsatellite Instability

Share to Microsatellite Repeats

Share to Mutation

Share to Pancreatic Neoplasms

Source

Identifiers

PMID: 35512587
DOI: 10.1016/j.ejca.2022.03.033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.PMID 35512587Read ↗

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessSemantic proximity Read ↗

Comprehensive Genomic Analysis of the Prognostic and Immunological Characteristics of Tertiary Lymphoid structures and CD8+ T-cells in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancerSemantic proximity Read ↗

T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacySemantic proximity Read ↗

RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged Survival in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.Semantic proximity Read ↗

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.Semantic proximity Read ↗

Spatial distribution and activation changes of T cells in pancreatic tumors according to KRAS mutation subtypeSemantic proximity Read ↗

Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.Semantic proximity Read ↗

Spatially Resolved Epithelial States Delineate Immunosuppressive Niches of Impaired Myeloid Antigen Presentation in PDACSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.